Furthermore, aberrant HERG1 expression represents a clinically and biologically relevant feature during disease progression and a promising candidate as tumour marker and membrane therapeutic target for HNSCC treatment. The gene discussed is KCNH2; the disease is head and neck squamous cell carcinoma.